A 31-year-old cisgender woman is seen in clinic to start injectable, long-acting cabotegravir for HIV preexposure prophylaxis (PrEP).
Which one of the following is TRUE regarding long-acting injectable cabotegravir for HIV PrEP?
Figure 1. Injectable Cabotegravir Dosing Schedule
Illustration: David H. Spach, MD
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 20th, 2023
September 20th, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5